Wu A M, Kabat E A, Weigert M G
Carbohydr Res. 1978 Oct;66:113-24. doi: 10.1016/s0008-6215(00)83244-9.
Two dextran-specific (PC 3858 and PC 3936) and one levan-specific (PC 3660) NZB myeloma proteins were studied by quantitative precipitin and precipitin-inhibition assays. Both myeloma antidextrans were alphaD-(1 leads to 6) specific and precipitated strongly with a synthetic, linear dextran, molecular weight 35,500, and with other dextrans. The two myeloma antidextrans differed with respect to their relative reactivities with dextrans containing various proportions of alpha-D-(1 leads to 6), alpha-D-(1 leads to 4)-like, and alpha-D-(1 leads to 3)-like linkages. In inhibition assays, the two antidextran myeloma proteins behaved differently from each other, from alpha-D-(1 leads to 6)-specific BALB/c myeloma antidextrans, and from the human antidextrans previously studied. Isomalto-oligosaccharides IM3, IM4, and IM5 were all equal in inhibitory power but were only about 60% as potent as IM6 and IM7, which also inhibited equally on a molar basis. Although precipitation with linear dextran suggests that both may have groove-type sites, as previously inferred for QUPC 52, the size of their combining sites is uncertain. It is not clear whether the sites are only as big as three glucose residues with the increased inhibition by six and seven glucose residues being attributable to partial bivalence and to their ability to combine in several ways along the chain, or whether the site is as big as six glucose residues with the increment in binding by the fourth and fifth glucose residues being minimal and the sixth contributing considerable additional binding-energy. The fructan-specific myeloma protein did not react with inulin, but reacted with many levans and with perennial rye-grass levan containing only beta-D-(2 leads to 6) links. The levan-antilevan reaction was not inhibited by beta-D-(2 leads to 1)- linked oligosaccharides. The findings suggest that PC 3660 has a specificity for (2 leads to 6)-linked chains.
通过定量沉淀和沉淀抑制试验研究了两种特异性结合右旋糖酐的(PC 3858和PC 3936)以及一种特异性结合果聚糖的(PC 3660)新西兰黑鼠骨髓瘤蛋白。两种骨髓瘤抗右旋糖酐蛋白均对α-D-(1→6)具有特异性,能与一种分子量为35,500的合成线性右旋糖酐以及其他右旋糖酐强烈沉淀。这两种骨髓瘤抗右旋糖酐蛋白在与含有不同比例α-D-(1→6)、α-D-(1→4)样和α-D-(1→3)样连接键的右旋糖酐的相对反应性方面存在差异。在抑制试验中,这两种抗右旋糖酐骨髓瘤蛋白彼此表现不同,与α-D-(1→6)特异性的BALB/c骨髓瘤抗右旋糖酐蛋白不同,也与先前研究的人抗右旋糖酐蛋白不同。异麦芽糖寡糖IM3、IM4和IM5的抑制能力相同,但仅约为IM6和IM7的60%,而IM6和IM7在摩尔基础上的抑制能力也相同。虽然与线性右旋糖酐的沉淀表明两者可能都有凹槽型位点,如先前对QUPC 52的推断,但其结合位点的大小尚不确定。不清楚这些位点是否仅与三个葡萄糖残基大小相同,六个和七个葡萄糖残基抑制作用的增强是由于部分二价性以及它们沿链以多种方式结合的能力,还是位点与六个葡萄糖残基大小相同,第四个和第五个葡萄糖残基结合的增加最小,而第六个葡萄糖残基贡献了相当大的额外结合能。果聚糖特异性骨髓瘤蛋白不与菊粉反应,但与许多果聚糖以及仅含β-D-(2→6)连接键的多年生黑麦草果聚糖反应。果聚糖-抗果聚糖反应不受β-D-(2→1)连接的寡糖抑制。这些发现表明PC 3660对(2→6)连接的链具有特异性。